Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia
This report provides summarised updates on adverse events following immunisation (AEFIs) of COVID-19 Vaccines in Malaysia.
To receive the latest issues of summary report, you may join the NPRA Safety Information Mailing List by filling out the subscription form at https://forms.gle/x7eim2Z99HKVNSsz6.
Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 10 Jun 2022)
Pengenalan
- Bagaimana NPRA mengumpul laporan kesan advers?
- Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?
Jumlah Dos Vaksin COVID-19 Yang Diberikan
Kadar Pelaporan Kesan Advers
- Respon AEFI yang diterima melalui aplikasi MySejahtera
- Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
- Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
- Pelaporan AEFI vaksin COVID-19 bagi golongan remaja berusia 12-17 tahun
- Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun
Adverse Events of Special Interest (AESI)
Rumusan
- Manfaat pemberian vaksin COVID-19 melebihi risikonya
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 10th June 2022)
Introduction
- How does NPRA collect adverse event reports?
- How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- Booster doses (PICK-B)
- COVID-19 vaccination in adolescents aged 12 to 17 years
- COVID-19 vaccination in children aged 5 to 11 years
Adverse Events of Special Interest
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 11th March 2022)
Introduction
- How NPRA collects adverse event reports?
- How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- Booster doses (PICK-B)
- COVID-19 vaccination in children aged 5 to 11 years (PICKids)
Adverse Events of Special Interest
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 31st December 2021)
Introduction
- How NPRA collects adverse event reports?
- How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
- COVID-19 vaccination in the age of 12 to 17 years
- Booster doses
Adverse Events of Special Interest
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 29th October 2021)
Introduction
- How NPRA collects adverse event reports?
- How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?
Total Doses of COVID-19 Vaccines Administered
Rate of Reported Adverse Events
- AEFI responses received via MySejahtera application
- AEFI reports received via NPRA Reporting System
Summary
- Protective benefits of COVID-19 vaccination outweigh the potential risks
